-+ 0.00%
-+ 0.00%
-+ 0.00%

HC Wainwright & Co. Reiterates Buy on Hemab Therapeutics Hldgs, Maintains $40 Price Target

Benzinga·06/26/2026 17:34:58
Listen to the news
HC Wainwright & Co. analyst Emily Bodnar reiterates Hemab Therapeutics Hldgs (NASDAQ:COAG) with a Buy and maintains $40 price target.